Skip to content

Capmatinib

Also known as Tabrecta (us)

Cancer & Oncology
Save $5,510/mo
15× cheaper

Capmatinib is used to treat a certain type of non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Capmatinib is in a class of medications called kinase inhibitors.

United States
$5,914
per month
India
$404
per month
You save
$5,510
93% cheaper in India
6.5K US scripts/yr$35.7M potential annual savings$38.3M US spend/yr
Building 3D structure…
Drag to rotate · 3D structureC23H17FN6O

SMILES: CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F

Compare the price
US price$5,914per month
India price$404per month
You save$5,51093% less

Based on 30 units per month. US $197.14 vs India $13.47 per unit.

Total over 1 periodSave $5,510$5,914$404
Is travelling to India worth it?

The savings here are large enough that a trip may still come out ahead. Adjust the numbers to your own situation — every value is an editable estimate.

Medicine savings over 6 months
$33,062
Estimated travel cost
− $2,300
Net savings after travel
$30,762

Even after travel, you could come out ahead by about $30,762.

Assumptions: medicine savings = (US − India monthly price) × months. Travel cost = flights + hotel × nights + buffer. Excludes consultation fees, visas, and other costs. For information only — not medical, legal, or travel advice.

The bigger picture

Capmatinib is filled about 6.5K times a year under Medicare Part D. At the prices above, that works out to roughly:

Est. annual US spend
$38.3M
If sourced from India
$2.6M
Potential annual savings
$35.7M
93%

Rough estimate. Based on Medicare Part D prescription volume (not the entire US market) scaled by the representative monthly price — actual totals depend on dose, duration and coverage.